The ISSCR today underscored the need for careful oversight and regulation of stem cell research at every stage in the process of developing therapeutic products for patient use.

The ISSCR supports the continued assessment of the U.S. National Institutes of Health (NIH) Guidelines for Human Stem Cell Research. We applaud the proposed end to the current moratorium on U.S. federal funding of human-animal chimera research involving the introduction of human pluripotent cells into early stage animal embryos.

The ISSCR is pleased that the U.S. National Institutes of Health (NIH) is considering an end to the moratorium on NIH funding of human-animal chimera research (NIH Notice, 8-4-16).

The ISSCR provided comments to the National Academy of Science/National Academy of Medicine Committee on Human Gene Editing regarding scientific, medical, and ethical considerations.

The ISSCR, the world’s largest professional organization of stem cell scientists, today released newly updated guidelines for stem cell research and the development of new clinical therapies. Guidance addresses key scientific, ethical, social, and policy challenges raised by new technologies and emerging areas of stem cell discovery and application.

The International Society for Stem Cell Research (ISSCR) is the world’s leading professional organization of stem cell scientists, representing more than 4,000 members in 45 U.S. states and 65 countries around the world. The ISSCR is opposed to recent efforts to inappropriately limit or prohibit biomedical research using fetal tissue. These proposals, if enacted, would obstruct critical biomedical research and inhibit efforts to improve human health. If enacted in the past, such limits would have delayed or prevented the development of therapies that have saved millions of lives.

In response to an article published by Chinese scientists describing research that used gene editing technologies in human embryos, the International Society for Stem Cell Research (ISSCR) has again called for a moratorium on attempts at human clinical germline genome editing while extensive scientific analysis of the potential risks is conducted, along with broad public discussion of the societal and ethical implications.

The International Society for Stem Cell Research calls for a moratorium on attempts at clinical application of nuclear genome editing of the human germ line to enable more extensive scientific analysis of the potential risks of genome editing and broader public discussion of the societal and ethical implications.

The ISSCR welcomes the recent EU Commission’s response to concerns about how funding from the Horizon 2020 EU Research and Innovation program is to be used for human embryonic stem cell research. The ISSCR advocates that all forms of stem cell research are crucial for the advancement of our understanding of human health and disease and for the development of novel treatments.

The International Society for Stem Cell Research (ISSCR) urges medical licensing bodies, legal authorities, patient advocacy organizations, physicians, and others to exercise their influence to discourage commercial provision of unproven autologous cell-based interventions outside of clinical trials.

The ISSCR urges Italian lawmakers to heed concerns of scientists around the world about the premature practice of unproven stem cell treatments and to recognize the importance of regulatory oversight and patient protection when developing new stem cell medicines.

The International Society for Stem Cell Research (ISSCR) voices concern as the Italian government authorizes an unproven stem cell therapy for use in patients.

The ISSCR further congratulates Drs. Shinya Yamanaka and John Gurdon for their scientific achievements recognized by this year's Nobel Prize and reaffirms support for all forms of stem cell research.

The ISSCR is concerned that some stem cell treatments are being prematurely offered to patients without safeguards in place to ensure safety and efficacy.

Vital progress in stem cell research by hundreds of U.S. laboratories is threatened after last week’s injunction prohibiting federal funding for the study of human embryonic stem cells (hESCs).